These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 26767080)

  • 21. Long-Term Effects of Ipragliflozin on Diabetic Nephropathy and Blood Pressure in Patients With Type 2 Diabetes: 104-Week Follow-up of an Open-Label Study.
    Ito D; Inoue K; Sumita T; Hamaguchi K; Kaneko K; Yanagisawa M; Inukai K; Inoue I; Noda M; Shimada A
    J Clin Med Res; 2018 Sep; 10(9):679-687. PubMed ID: 30116437
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of Ipragliflozin on Diabetic Nephropathy and Blood Pressure in Patients With Type 2 Diabetes: An Open-Label Study.
    Ito D; Ikuma-Suwa E; Inoue K; Kaneko K; Yanagisawa M; Inukai K; Noda M; Shimada A
    J Clin Med Res; 2017 Feb; 9(2):154-162. PubMed ID: 28090231
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-World Clinical Effectiveness and Tolerability of Hydroxychloroquine 400 Mg in Uncontrolled Type 2 Diabetes Subjects who are not Willing to Initiate Insulin Therapy (HYQ-Real-World Study).
    Gupta A
    Curr Diabetes Rev; 2019; 15(6):510-519. PubMed ID: 31713476
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differing Effect of the Sodium-Glucose Cotransporter 2 Inhibitor Ipragliflozin on the Decrease of Fat Mass vs. Lean Mass in Patients With or Without Metformin Therapy.
    Nagai Y; Fukuda H; Kawanabe S; Nakagawa T; Ohta A; Tanaka Y
    J Clin Med Res; 2019 Apr; 11(4):297-300. PubMed ID: 30937121
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ipragliflozin effectively reduced visceral fat in Japanese patients with type 2 diabetes under adequate diet therapy.
    Yamamoto C; Miyoshi H; Ono K; Sugawara H; Kameda R; Ichiyama M; Yamamoto K; Nomoto H; Nakamura A; Atsumi T
    Endocr J; 2016 Jun; 63(6):589-96. PubMed ID: 27052123
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Open-Label Study to Assess the Efficacy of Ipragliflozin for Reducing Insulin Dose in Patients with Type 2 Diabetes Mellitus Receiving Insulin Therapy.
    Ishihara H; Yamaguchi S; Sugitani T; Kosakai Y
    Clin Drug Investig; 2019 Dec; 39(12):1213-1221. PubMed ID: 31552641
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination treatment with ipragliflozin and metformin: a randomized, double-blind, placebo-controlled study in patients with type 2 diabetes mellitus.
    Veltkamp SA; van Dijk J; Collins C; van Bruijnsvoort M; Kadokura T; Smulders RA
    Clin Ther; 2012 Aug; 34(8):1761-71. PubMed ID: 22795925
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effects of ipragliflozin on the liver-to-spleen attenuation ratio as assessed by computed tomography and on alanine transaminase levels in Japanese patients with type 2 diabetes mellitus.
    Bando Y; Ogawa A; Ishikura K; Kanehara H; Hisada A; Notumata K; Okafuji K; Toya D
    Diabetol Int; 2017 Jun; 8(2):218-227. PubMed ID: 30603325
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ipragliflozin: A novel sodium-glucose cotransporter 2 inhibitor developed in Japan.
    Ohkura T
    World J Diabetes; 2015 Feb; 6(1):136-44. PubMed ID: 25685284
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial.
    Bode B; Stenlöf K; Sullivan D; Fung A; Usiskin K
    Hosp Pract (1995); 2013 Apr; 41(2):72-84. PubMed ID: 23680739
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-world evidence for the safety of ipragliflozin in elderly Japanese patients with type 2 diabetes mellitus (STELLA-ELDER): final results of a post-marketing surveillance study.
    Yokote K; Terauchi Y; Nakamura I; Sugamori H
    Expert Opin Pharmacother; 2016 Oct; 17(15):1995-2003. PubMed ID: 27477242
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of the combination of SGLT2 selective inhibitor ipragliflozin and various antidiabetic drugs in type 2 diabetic mice.
    Tahara A; Takasu T; Yokono M; Imamura M; Kurosaki E
    Arch Pharm Res; 2016 Feb; 39(2):259-270. PubMed ID: 26450351
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ipragliflozin lowers small, dense low-density lipoprotein cholesterol levels in Japanese patients with type 2 diabetes mellitus.
    Bando Y; Tohyama H; Aoki K; Kanehara H; Hisada A; Okafuji K; Toya D
    J Clin Transl Endocrinol; 2016 Dec; 6():1-7. PubMed ID: 29067237
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and effectiveness of ipragliflozin in Japanese patients with type 2 diabetes mellitus and impaired renal function: subgroup analysis of a 3-year post-marketing surveillance study (STELLA-LONG TERM).
    Tobe K; Maegawa H; Nakamura I; Uno S
    Diabetol Int; 2021 Apr; 12(2):181-196. PubMed ID: 33786273
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and Effectiveness of Ipragliflozin in Elderly Versus Non-elderly Japanese Patients with Type 2 Diabetes: Subgroup Analysis of STELLA-LONG TERM.
    Nakamura I; Maegawa H; Tobe K; Uno S
    Diabetes Ther; 2021 May; 12(5):1359-1378. PubMed ID: 33730336
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Study of the effect of the herbal composition SR2004 on hemoglobin A1c, fasting blood glucose, and lipids in patients with type 2 diabetes mellitus.
    Chatterji S; Fogel D
    Integr Med Res; 2018 Sep; 7(3):248-256. PubMed ID: 30271713
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Two-year administration of sodium-glucose co-transporter 2 inhibitor brought about marked reduction of body fat independent of skeletal muscle amount or glycemic improvement in Japanese patients with type 2 diabetes.
    Sakamoto M; Goto Y; Nagayama A; Yano M; Sato S; Tajiri Y; Nomura M
    Diabetol Int; 2022 Jan; 13(1):117-123. PubMed ID: 35059247
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of metabolic parameters and body composition in Japanese patients with type 2 diabetes mellitus who were administered tofogliflozin for 48 weeks.
    Iwahashi Y; Hirose S; Nakajima S; Seo A; Takahashi T; Tamori Y
    Diabetol Int; 2017 Jun; 8(2):205-211. PubMed ID: 30603323
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical response to sodium glucose co-transporter 2 inhibitor ipragliflozin in a patient with metastatic renal cell carcinoma.
    Izumi K; Iimura Y; Hiruma K; Touma T; Tsukamoto T
    IJU Case Rep; 2019 Sep; 2(5):269-271. PubMed ID: 32743434
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correction: Efficacy and Safety of Ipragliflozin in Japanese Patients With Type 2 Diabetes: Interim Outcome of the ASSIGN-K Study.
    Iizuka T; Iemitsu K; Takihata M; Takai M; Nakajima S; Minami N; Umezawa S; Kanamori A; Takeda H; Kawata T; Ito S; Kikuchi T; Amemiya H; Kaneshiro M; Mokubo A; Takuma T; Machimura H; Tanaka K; Asakura T; Kubota A; Aoyagi S; Hoshino K; Ishikawa M; Matsuzawa Y; Obana M; Sasai N; Kaneshige H; Minagawa F; Saito T; Shinoda K; Miyakawa M; Tanaka Y; Terauchi Y; Matsuba I
    J Clin Med Res; 2016 Mar; 8(3):267. PubMed ID: 26858805
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.